This refers to Receptor Antagonists compounds sphingosine 1 - phosphate (S1P), Methods for production thereof, Pharmaceutical compositions containing same.And Methods of treatment that are used for the prophylaxis and / or treatment of diseases involving fibrotic diseases, inflammatory diseases, autoimmune diseases,Metabolic Diseases, cardiovascular diseases and / or proliferative diseases by Administering the compound of the present.Claim 1: a compound according to formula (1),Where X is o or n = = CN； r u00b9 u1d43 is selected: rent c u2081 u208b u2084 optionally substituted with one or More groups independently selected ohC u2081 u208b u2084 alkoxy optionally substituted with one or more Oh - or alkoxy c u2081 u208b u2084 independently selected, SO u2082 c u2081 u208b u2084 alkyl or cycloalkyl c u2083 u208b u2087 monocyclic -, -, and - or - heterocicloalquilo,Where such heterocicloalquilo is a monocyclic heterocicloalquilo 4 - 7 members comprising one, two, or three heteroatoms selected regardless of N,And S - or alkoxy； nr u2076 u1d43r u2076 u1d47； c u2081 u208b u2084 cycloalkyl c u2083 u208b u2087 heterocicloalquilo monocyclic； monoclinic； 4 - 7 members comprising one, two, or three heteroatoms selected regardless of N, o and SOptionally substituted with one or more halos； or cycloalkyl c u2083 u208b u2087 monocyclic； and - or - heterocicloalquilo,Where such heterocicloalquilo is a monocyclic heterocicloalquilo 4 - 7 members comprising one, two, or three heteroatoms selected regardless of N,O and S； r u00b9 u1d47 is H or alkyl c u2081 u208b u2084； cy u00b9 monocyclic heteroaryl ring is a 5 Member, which comprises One, two or three heteroatoms selected regardless of N, o or s,Or cy u00b9 is a monocyclic Ring heterocicloalquilo 4 - 7 members comprising one, two, or three heteroatoms selected regardless of N, o or s,Heterocicloalquilo monocyclic Ring or a 4 - 7 members comprising one, two, or three heteroatoms selected regardless of N, o or s,Heteroaryl fused wi
